Rob Wright interviews Jeremy Levin, chairman and CEO of Ovid Therapeutics, about the BIO opioid crisis working group he is chairing.
Rob Wright video interviews Michael Margolis, R.Ph, head of life sciences and co-head of healthcare investment banking at Oppenheimer & Co. Inc. during the 2018 BIO CEO & Investor Conference in New York.
Rob Wright video interviews CytoSorbents’ CEO, Dr. Philip Chan, about CytoSorb, the company’s lead product described as a “Brita filter for your blood,” during the 2018 BIO CEO & Investor Conference in New York.
Rob Wright video interviews Atreca CEO, Tito Serafini, during the 2018 BIO CEO & Investor Conference in New York about the company’s search for antigens that are driving successful immune responses in cancer patients.
How the 10 largest publicly traded biopharmaceutical companies compare to 10 of the largest publicly traded nonbiopharmaceutical companies in the area of gender diversity among executive leadership.
An inside look into how this fledgling biopharma has raised over $150 million and enlisted two high-profile CEOs from one of the hottest VC firms around, all in less than two years.
How can we address challenges that have plagued our past, such as egregious drug price increases, corruption, collusion, deception, and unethical marketing practices?
With President Trump’s recently announced focus on reducing the price of prescription drugs, perhaps it is time branded biopharmaceutical companies consider competing in other areas beyond just biosimilars (i.e., generic biologics).
Successful drug discovery and development requires a passionate commitment, something that can only be displayed during the breakout sessions at the J.P. Morgan annual healthcare conference.